crossmark
Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe Muhammad-Hariri Mustafa,a,b Hussein Chalhoub,a Olivier Denis,c Ariane Deplano,c Anne Vergison,c* Hector Rodriguez-Villalobos,d Michael M. Tunney,e J. Stuart Elborn,e Barbara C. Kahl,f Hamidou Traore,b Francis Vanderbist,b Paul M. Tulkens,a Françoise Van Bambekea Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgiuma; SMB Laboratories, Brussels, Belgiumb; Hôpital Erasme/Hôpital des Enfants Malades, Université libre de Bruxelles, Brussels, Belgiumc; Department of Microbiology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgiumd; The Queen’s University of Belfast, Belfast, United Kingdome; University Hospital Münster, Münster, Germanyf
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This study compared the antimicrobial susceptibilities of 153 P. aeruginosa isolates from the United Kingdom (UK) (n ⴝ 58), Belgium (n ⴝ 44), and Germany (n ⴝ 51) collected from 118 patients during routine visits over the period from 2006 to 2012. MICs were measured by broth microdilution. Genes encoding extended-spectrum -lactamases (ESBL), metallo--lactamases, and carbapenemases were detected by PCR. Pulsed-field gel electrophoresis and multilocus sequence typing were performed on isolates resistant to >3 antibiotic classes among the penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and polymyxins. Based on EUCAST/CLSI breakpoints, susceptibility rates were
Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe Muhammad-Hariri Mustafa,a,b Hussein Chalhoub,a Olivier Denis,c Ariane Deplano,c Anne Vergison,c* Hector Rodriguez-Villalobos,d Michael M. Tunney,e J. Stuart Elborn,e Barbara C. Kahl,f Hamidou Traore,b Francis Vanderbist,b Paul M. Tulkens,a Françoise Van Bambekea Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgiuma; SMB Laboratories, Brussels, Belgiumb; Hôpital Erasme/Hôpital des Enfants Malades, Université libre de Bruxelles, Brussels, Belgiumc; Department of Microbiology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgiumd; The Queen’s University of Belfast, Belfast, United Kingdome; University Hospital Münster, Münster, Germanyf
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This study compared the antimicrobial susceptibilities of 153 P. aeruginosa isolates from the United Kingdom (UK) (n ⴝ 58), Belgium (n ⴝ 44), and Germany (n ⴝ 51) collected from 118 patients during routine visits over the period from 2006 to 2012. MICs were measured by broth microdilution. Genes encoding extended-spectrum -lactamases (ESBL), metallo--lactamases, and carbapenemases were detected by PCR. Pulsed-field gel electrophoresis and multilocus sequence typing were performed on isolates resistant to >3 antibiotic classes among the penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and polymyxins. Based on EUCAST/CLSI breakpoints, susceptibility rates were
